English | QuidelOrtho

QuidelOrtho launches Vitros^® Syphilis Assay

Vitros^® syphilis assay is now available on the Vitros 3600 Immunodiagnostic System and Vitros 5600 and Vitros XT 7600 Integrated Systems in the U.S.

Fentanyl test now available on Vitros^® Systems

This MicroTip^® Partnership Assay will help hospitals and emergency rooms respond to the critical demand for enhanced opioid testing

Changing lives one test at a time

From home to hospital, lab to clinic, we deliver real-time, actionable intelligence powered by industry-leading expertise.

QuidelOrtho launches Vitros® Syphilis Assay
QuidelOrtho adds Fentantyl test to Vitros®
Changing lives, one test at a time

Committed to people, planet and products

Inspiring and leading QuidelOrtho

Featured products

Solana^® Molecular Testing Platform

Learn more

Sofia^® Platform

Learn more

Ortho^® Workstation Immunohematology Analyzer

Learn more

Ortho Optix™ Reader

Learn more

Lyra^® Assays

Learn more

QuickVue^® Rapid Lateral-Flow Tests

Learn more

Vitros^® Systems

Learn more

Triage^® System

Learn more

Ortho Vision^® Swift Automated Immunohematology System

Learn more

Featured products

View all products

In global pursuit of better health outcomes

We are driven to transform diagnostic data into answers, understanding and action for more people in more places every day. Learn how we help you chart the course forward in care.

News & Events

Press Release 11/16/23

QuidelOrtho to Participate in the Evercore ISI Conference

Press Release 11/01/23

QuidelOrtho Reports Third Quarter 2023 Financial Results

Press Release 10/12/23

QuidelOrtho Reports Preliminary Revenue Results For The Third Quarter 2023

Press Release 09/21/23

Quidelortho Receives CLIA Waiver For Sofia^® 2 SARS Antigen+ FIA

Press Release 08/28/23

QuidelOrtho to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Press Release 08/11/23

QuidelOrtho Appoints Juliet Cunningham As Vice President Of Investor Relations

Press Release 08/09/23

QuidelOrtho Reports Second Quarter 2023 Financial Results

Press Release 07/25/23

QuidelOrtho Ranks No. 1 in Customer Satisfaction for Six Years in a Row

Press Release 07/24/23

QuidelOrtho Partners With BYG4lab® to Strengthen Informatics Offerings

Press Release 07/18/23

QuidelOrtho to Report Second Quarter 2023 Financial Results

Press Release 05/23/23

QuidelOrtho to Participate in William Blair 43rd Annual Growth Stock Conference

Press Release 05/08/23

QuidelOrtho Receives FDA De Novo Classification for Two SARS-CoV-2 Antibody Tests

Legal Notice

By accessing, browsing, and/or using this website, you acknowledge that you have read, understood, and agree to be bound by QuidelOrtho’s Website Terms of Use, Privacy Notice and to comply with all applicable laws and regulations. If you do not agree to these terms, do not use the website. Additionally, the website contains information on products that is targeted to many different audiences and could contain product details or information otherwise not accessible or valid in your country. Product availability may vary from country to country and is subject to varying regulatory requirements. New QuidelOrtho branding may not be available in all markets, subject to country specific regulatory approval. Please be aware that we do not take any responsibility for your accessing such information that may not comply with any legal process, regulation, registration, or usage in the country of your origin.

©2024 QuidelOrtho Corporation. All rights reserved.

QuidelOrtho Corporation
9975 Summers Ridge Road, San Diego, CA 92121, USA